Clinical Trials Arena on MSN
UCB’s Bimzelx bests Skyrizi in Phase III PsA study, but analysts sceptical
While this result affirms Bimzelx’s efficacy in PsA, analysts do not believe this readout will have a notable impact on the drug’s uptake or sales.
In early March 2026, AbbVie reported positive topline Phase 3 AFFIRM data showing risankizumab (SKYRIZI) subcutaneous ...
NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately ...
AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3, randomized, placebo-controlled, double-blind AFFIRM study evaluating the efficacy and safety of risankizumab (SKYRIZI®) ...
NORTH CHICAGO, Ill., June 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from COMMAND, its Phase 3 maintenance study, showing risankizumab (SKYRIZI ®, 180 mg or ...
On Wednesday, AbbVie Inc. (NYSE:ABBV) reported third-quarter adjusted EPS of $3.00, up from $2.95 a year ago, beating the consensus of $2.92. Net revenues reached $14.46 billion, up 3.8%, beating the ...
AbbVie ABBV announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion, recommending approval of Skyrizi ...
Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...
Hosted on MSN
AbbVie’s Power Play: How Skyrizi, Rinvoq, and a Surging Brain Business Are Crushing It (Even if Botox Isn't)
The worry with Abbvie was that once the Humira patent expired, this would be a business in huge decline. Well, the patent expired and two new drugs took the torch. During their latest earnings call, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results